Sage Journals: Discover world-class research

Abstract

Spanish

French

OBJECTIVE:

To assess the reliability and validity of a proposed new standard of drug-use intensity, the minimum marketed dose (MMD), using anxiolytic drugs as models.

DESIGN:

Retrospective, cohort design.

SETTING:

Staff model, nonprofit health maintenance organization.

PATIENTS/PARTICIPANTS:

Eighty-five patients who obtained one or more prescriptions for an anxiolytic, antidepressant, or sedative-hypnotic drug during three consecutive one-year time periods. Fifty-nine patients had a prescription filled during the year before the study.

RESULTS:

For anxiolytic drugs, the magnitude of the average correlation for the MMD measure of drug-use intensity was greater than the total number of prescriptions and the total number of dosage units. Discriminant validity was demonstrated because the MMD was not correlated with measures in unrelated therapeutic categories. Summed MMD units were shown to significantly predict physical impairment (criterion validity).

CONCLUSIONS:

The MMD measure of drug-use intensity was reliable and valid for anxiolytic drugs. These findings suggest that information gathered from automated prescription records may be a useful indicator of drug-use intensity in pharmacoepidemiologic studies.

Get full access to this article

View all access options for this article.

References

Bradford-Hill

. The environment and disease: Association or cause? Proc Roy Soc Med 1965; 58: 295–300.

Serradel

Bjornson

Hartzema

. Drug utilization study methodologies: National and international perspectives. Drug Intell Clin Pharm 1987; 21: 994–1001.

Davis

. Comparative doses and costs of antipsychotic medication. Arch Gen Psychiatry 1976; 33: 858–61.

Zito

Craig

Wanderlin

Siegel

. Pharmaco-epidemiology in 136 hospitalized schizophrenic patients. Am J Psychiatry 1987; 144: 778–82.

Pearson

Grothaus

Thompson

Wagner

. Smokers and drinkers in a health maintenance organization: Lifestyles and health status. Prev Med 1987; 16: 783–95.

Campbell

Fiske

. Convergent and discriminant validation by the multitrait-multimethod. Psychol Bull 1955; 56: 81–105.

Kerlinger

. Foundations of behavioral research. 2nd ed. New York: Holt, Rinehart and Winston, 1973: 459–60.

Ried

Christensen

Stergachis

. Medical and psychosocial factors predictive of psychotropic drug use in elderly patients. Am J Pub Health 1990; 80: 1349–53.

Larson

Kukull

Buchner

Reifler

. Adverse drug reactions associated with global cognitive impairment in elderly patients. Ann Intern Med 1987; 107: 169–73.

10.

Whitcup

Miller

. Unrecognized drug dependence in psychiatrically hospitalized elderly patients. J Am Geriatr Soc 1987; 35: 297–301.

11.

Schneider-Helmert

. Why low dose benzodiazepine-dependent insomniacs can't escape their sleeping pills. Acta Psychiatr Scand 1988; 78: 706–11.

12.

Ray

Griffin

Schaffner

Baugh

Melton

. Psychotropic drug use and risk of hip fracture. N Engl J Med 1987; 316: 363–9.

13.

AMA drug evaluations. 5th ed. Chicago: American Medical Association, 1983.

14.

Jick

Walker

Watkins

D'Ewart

Hunter

Danford

. Oral contraceptives and breast cancer. Am J Epidemiol 1980; 112: 577–85.

15.

Stergachis

. Group health cooperative. In: Strom

, ed. Pharmacoepidemiology. London: Churchill Livingstone, 1989: 149–60.

16.

Physicians' desk reference. 42nd ed. Oradell, NJ: Medical Economics, 1988.

17.

Treatments of psychiatric disorders: a task force report of the American Psychiatric Association. Washington DC: American Psychiatric Association, 1989: 2040.

18.

Mellinger

Balter

Uhlenhuth

. Prevalence and correlates of long-term regular users of psychotropics. JAMA 1984; 251: 375–9.

19.

Mellinger

Balter

Manheimer

Cisin

Parry

. Psychic distress, life crisis, and use of psychotherapeutic medications. Arch Gen Psychiatry 1978; 35: 1045–52.

Evaluation of the Reliability and Validity of a Measure of Anxiolytic Drug-Use Intensity for Pharmacoepidemiologic Studies